Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 3/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | PNMT | P11086 | 4/20 | 0.44 |
| ▸ | CD44 | P16070 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17965627 | 0.98 | ASIC3 (0.49) | ASIC3DRD2DRD3HRH3PNMT | |
| SCHEMBL21753264 | 0.90 | ADRA2A (0.51) | DRD2HRH3CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL8263140 | 0.86 | CHRNB2 (0.47) | DRD2HRH3CHRNB2CHRNA7CHRNA4 | |
| Hydrochloric Acid SCHEMBL31084083 | 0.84 | CHRNB2 (0.46) | DRD2HRH3CHRNB2CHRNA7CHRNA4 | |
| SCHEMBL17583864 | 0.83 | ASIC3 (0.50) | ASIC3DRD2DRD3HRH3PNMT | |
| SCHEMBL7979150 | 0.80 | ASIC3 (0.50) | ASIC3DRD2DRD3HRH3PNMT | |
| SCHEMBL17585077 | 0.80 | HRH3 (0.53) | ASIC3DRD2DRD3HRH3PNMT | |
| Hydrochloric Acid SCHEMBL7643355 | 0.79 | ASIC3 (0.49) | ASIC3DRD2DRD3HRH3PNMT | |
| SCHEMBL8467911 | 0.77 | CD274 (0.59) | ASIC3DRD2DRD3HRH3PNMT | |
| SCHEMBL532484 | 0.77 | CD274 (0.59) | ASIC3DRD2DRD3HRH3PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-18 | — | — | US | disclosed |
| EP-3053917-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nissan Chemical Industries, Ltd. (JP) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015050212-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 日産化学工業株式会社 | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1I, CACNA1G, CACNA1H | ASIC3 157/4885DRD2 935/4885DRD3 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.